Eirgen Pharma has appointed two of its senior leaders to newly defined executive roles, reinforcing the company’s leadership structure as it continues to scale its global operations and manufacturing capabilities.
James Murphy has been named as Chief Operating Officer and Jan Willem (JW) Blüm has been named as Chief Finance Officer.
Damien Burke, CEO of Eirgen Pharma, said; “These appointments are a vital step in our maturation as an organization. By elevating leaders who have been integral to our recent successes, we are ensuring both continuity and heightened focus on our operational and financial discipline necessary to navigate our next phase of growth.”
James Murphy, Chief Operating Officer
Since joining Eirgen in 2021 as Head of Engineering, Murphy has been instrumental in the expansion of the company’s high-potency development and commercial manufacturing infrastructure.
With over 20 years of experience across research, product development, and manufacturing engineering, Murphy is positioned to lead Eirgen’s operational future. In his new role, he will oversee Manufacturing, Packaging, Supply Chain, Business Development, Engineering, Facilities, EHS, and Operational Excellence, ensuring continued stability and coordinated performance across all production and development activities.
Jan Willem Blüm, Chief Finance Officer
Blüm joined Eirgen in 2021 as Head of Finance and brings over 19 years of extensive international leadership experience, with a background spanning financial planning, logistics, IT, and marketing across several European markets. As CFO, he will oversee Financial Strategy and Governance, IT, HR, Learning & Development, and Legal.
Blüm’s focus will be to ensure Eirgen’s organizational systems, financial planning, and cross-functional processes effectively align the company’s human capital and financial investments with its long-term strategic objectives.
